100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapy Complete responses (“CRs”) are rarely (0-8%) observed in metastatic pancreatic cancer in published studies evaluating chemotherapy-, checkpoint inhibitor-, and RAS inhibitor-based regimens ELI-002 7P-induced mutant KRAS(“mKRAS”)-specific T cells may synergize with checkpoint inhibition to allow deep antitumor responses in a tumor type previously considered refractory to immunotherapy Elicio believes these post-study observations build on mechanistic validation from prior AMPLIFY studies and support evaluation of ELI-002 7P in combination with checkpoint inhibition in metastatic pancreatic cancer Elicio intends to initiate a Phase 1 study in metastatic pancreatic ductal adenocarcinoma (“PDAC”) designed to provide a rapid assessment of clinical activity through a focused, confirmatory study, subject to funding Elicio plans to use the study findings to further evaluate checkpoint inhibitor combinations and help inform future development strategies in metastatic PDAC and the adjuvant PDAC Phase 3 trial Elicio is hosting a virtual key opinion leader event on Wednesday, June 24, 2026, at 1:00 PM ET, to further discuss these observations BOSTON, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today reported preliminary clinical observations which the Company believes support the evaluation of ELI-002 7P in combination with checkpoint inhibition.